As someone just getting started in IC, this talk by @jaygirimd was inspiring. #VTE/#PERT is such an exciting space with rapid development & study 🙌🏽

(Also shoutout to my mentor @GoldbergJBCTMD who’s work is displayed in Dr Giri’s slides)

My takeaways, a🧵:
(1/6)
#Fellows2023 🔹Risk stratification and patient selection is key.

🔸Risk scores may not accurately stratify younger patients

🔹Full risk assessment has to include with the bedside eval w/ imaging + lab markers as adjunctive data

🔸Be on the lookout for normotensive shock

#Fellows2023 (2/6)

@djc795 with his top 10 historical #IC trials to know; studies that have had fundamental impact on the field

(Note, this is a summary, but really was a lecture to attend in person. Phenomenal & super fun)

@rwyeh @nadia_sutton @DougDrachmanMD @SrihariNaiduMD
A thread🧵:
(1/6) 1️⃣ ACME & RITA2 - SIHD, randomized PCI v meds -> ⬇️angina (CCS class)

2️⃣ BOAT - directional atherectomy, “bigger is better”. Luminal gain is🤴🏼.

3️⃣ BARI & FREEDOM - angioplasty vs CABG, important interaction of diabetes; LIMA is 🔑

#Fellows2023 @crfheart
(2/6)